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Edited by Thomas L. JamesAbstract PRL-3, a novel class protein of prenylated tyrosine
phosphatase, is important in cancer metastasis. Due to its high
levels of expression in metastatic tumors, PRL-3 may constitute
a useful marker for metastasis and might be a new therapeutic
target. Here, we present the solution structure of the phospha-
tase domain of a human PRL-3 (residues 1–162) in phosphate-
free state. The nuclear magnetic resonance (NMR) structure of
PRL-3 is similar to that of other known phosphatases with minor
diﬀerences in the secondary structure. But the conformation and
ﬂexibility of the loops comprising the active site diﬀer signiﬁ-
cantly. When phosphate ions or sodium orthovanadate, which is
a known inhibitor, are added to the apo PRL-3, the NMR signals
from the residues in the active site appeared and could be
assigned, indicating that the conformation of the residues has
been stabilized.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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PRL-1, -2, and -3 belong to a novel class of protein tyrosine
phosphatases (PTPs) with a C-terminal prenylation motif [1].
These are closely related intracellular enzymes that possess the
PTP active site signature sequence HCXXGXXR [2,3]. All
three proteins have molecular weights of about 20 kDa and
share at least 75% amino acid sequence similarity (Fig. 1).
PRL-1 is localized primarily in the brain andmuscle [3]. PRL-
2 is preferentially expressed in skeletal muscle, while PRL-3 is
found speciﬁcally in cardiac and skeletal muscles [3]. PRLs areq Supplementary data associated with this article can be found, in the
online version, at doi:10.1016/j.febslet.2004.03.062.
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doi:10.1016/j.febslet.2004.03.062more homologous to dual-speciﬁcity phosphatases (DSPs) than
to other tyrosine-speciﬁc PTPs, although PRL-1 can dephos-
phorylate phosphotyrosyl substrate in vitro [2]. Their highest
homology is with Cdc14 (20.3%) and with PTEN (16.9%).
To date, the cellular roles of none of the PRLs have been
determined. Recent serial analysis of gene expression experi-
ments has shown that PRL-3 is highly overexpressed in liver
metastases of colorectal cancer, but not in non-metastatic tu-
mors or in normal colorectal epithelium [4]. Furthermore,
causative roles for PRL-3 and -1 in promoting cell motility,
invasion activity, and metastasis have been reported [5]. While
a catalytically inactive PRL-3 mutant has signiﬁcantly reduced
migration-promoting activity, PRL-3- and -1-expressing cells
induce metastatic tumor formation in nude mice. These data
strongly suggest that the PRL-3 is important in cancer me-
tastasis and might provide a new therapeutic target for cancer
treatment.
Metastasis is the neoplastic process that is responsible for
most cancer deaths, as primary tumors can usually be removed
surgically. Metastatic cells undergo cytoskeletal changes, loss
of adhesion, and enhanced motility, and express proteolytic
enzymes that degrade the basement membrane. To understand
its mechanism at the atomic level and to discover candidate
drugs acting on PRL-3, it is important to determine its three-
dimensional structure.
Preliminary nuclear magnetic resonance (NMR) studies of
PRL-2 and -3 with backbone assignments have been reported
[6,7], and while we were preparing our manuscript, the struc-
ture of human PRL-3, solved independently by Kozlov et al.
[8], has recently appeared on internet. The structure solved by
Kozlov et al. is basically identical to ours except that their
structure is a complex structure with a phosphate group
whereas ours is an apo structure. When their structure was
overlaid on ours, the backbone root mean square deviation of
the secondary structure elements was 2.5 A.2. Materials and methods
2.1. Expression and puriﬁcation of the PRL-3 phosphatase domain
PRL-3 (aa 1–162) was cloned into pET21b vector (Novagen Inc.,
Madison, WI) and overexpressed in E. coli BL21(DE3) without tag or
fusion sequences. Isotopically enriched PRL-3 was prepared from cellsblished by Elsevier B.V. All rights reserved.
Table 1
Statistics of PRL-3 ﬁnal 20 structuresa
NOE restraints 2225
Intra (ji jj ¼ 0) 471
Sequential (ji jj ¼ 1) 609
Medium range (26 ji jj6 4) 472
Long range (ji jjP 5) 673
Dihedral angle restraints 143
Hydrogen bond restraints 27 2
Maximum violations
Distance (A) 0.22
Angle () 3.32
AMBER GB energies (kcal/mol)b
Total )6588 10
Van der Waals )1173 13
Electrostatic )10,750 403
Constraints 8 1
Mean deviations from ideal geometry
Bond lengths (A) 0.0106 0.0001
Bond angles () 2.21 0.02
Coordinate precision (residues 9–158)
Backbone (A) 0.76 0.10
Heavy atoms (A) 1.27 0.13
Ramachandran analysis
Most favored (%) 83.1
Additionally (%) 13.5
Generously (%) 2.7
Disallowed (%) 0.7
aAll variation is 1 S.D. if not speciﬁed.
b The generalized Born model of AMBER 7.
Fig. 1. Structure-based sequence alignment of PRLs, PTEN, PAC-1 and MKP-3. Secondary structure elements are underlined and color-coded.
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13C-glucose (Cambridge Isotopes Laboratory, Andover, MA). The
protein was puriﬁed by cation exchange chromatography followed by
size-exclusion chromatography. The protein was exchanged into an
appropriate buﬀer and was concentrated to a ﬁnal concentration of
20 mg/ml.
2.2. NMR spectroscopy
The NMR samples were 1 mM solutions in 50 mM HEPES buﬀer,
100 mM NaCl, and 10 mM dithiothreitol (DTT) at pH 7.3. The NMR
experiments were performed at 303 K on 600 MHz Bruker DRX600
(KBSI and NICEM) and 600 MHz Varian UNITY INOVA (KAIST)
spectrometers. The main-chain Ca, Ha, N, NH, and CO and side-chain
Cb resonances were assigned using HNCA, HN(CO)CA, HNCACB,
CBCA(CO)NH, HNCO, HN(CA) CO, and HNHA experiments [9].
The side-chain signal assignments were obtained from 1H–13C HSQC,
3D HCCH–COSY, CC(CO)NH, HCC(CO)NH, 1H–15N–HSQC
TOCSY, and 1H–15N–HSQC NOESY [10]. The stereospeciﬁc assign-
ment of the methyl groups of the Leu and Val residues was achieved
with a 20% fractionally 13C-labeled protein dissolved in 99.8% D2O, as
described [11]. Chemical shifts were measured relative to the internal
4,4-dimethyl 4-silapentane sodium sulfonate (DSS) for 1H and calcu-
lated for 13C and 15N [12]. Distance information was collected using 3D
(1H, 13C) and (1H, 15N) NOESY–HSQC spectra with 100 and 120 ms
mixing times. For torsion angle constraints, the backbone vicinal
coupling constants (3JHN;Ha) were estimated from a 3D HNHA spec-
trum [13] of uniformly 15N-labeled PRL-3.
2.3. Structure calculations
Structures were calculated by CYANA [14] and further reﬁned by
AMBER 7 package [15]. All the NOE cross peaks were assigned using
CANDID algorithm [16] of CYANA. Totally, 2225 meaningful NOE
upper distance restraints were obtained by CANDID. Backbone tor-
sion angle restraints of 143 were derived from HNHA experiment and
TALOS program [17] and 27 hydrogen bond restraints from the
backbone amides were added as distance restraints in regular sec-
ondary structures. With these restraints, ﬁnal 100 structures were
generated using 20 000 time steps of CYANA and further reﬁned by
AMBER. AMBER run consisted of 20 ps molecular dynamics, fol-
lowed by 1500 steps of energy minimization. To approximate solvent
interaction, generalized Born model was used [18]. The 20 structures
with lowest restraints energy were selected and analyzed using MOL-
MOL [19], AQUA, and PROCHECK-NMR software [20] (Table 1).
2.4. 15N relaxation measurements
The 15N longitudinal (R1) and transverse (R2) relaxation data were
collected using eight delays, namely 10–1280 ms for the T1 experiments
and 10–150 ms for the T2 experiments. The T1 and T2 values weredetermined by ﬁtting the peak heights as a function of the relaxation
interval (t) to a two-parameter (I0 and R1;2) exponential decay func-
tion, IðT Þ ¼ I0 expðR1;2tÞ, using a non-linear least squares analysis.3. Results and discussion
3.1. Assignment and structure determination
We performed NMR studies on the catalytic domain of
PRL-3 (aa 1–162). The C-terminal 11 residues, which include
Fig. 2. Structure of PRL-3 derived from NMR experiments. (A) The 20
backbone structures were superimposed. The residues in the helical
regions and in the b sheets are shown in blue and red, respectively. (B)
The ribbon diagram of one representative structure.
Fig. 3. A comparison of three structures. (A) PRL-3, (B) PAC-1, and
(C) PTEN. Residues Cys104 and Arg110 of PRL-3 are marked by
ﬁlled circles. Asp72 in the general acid loop of PRL-3 and the corre-
sponding residues in PAC-1 and PTEN are shown using a ball-and-
stick model.
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The speciﬁc activity of the catalytic domain of PRL-3 was 830
unit/mg/min, which is similar to that of the full-length PRL-3
(730 unit/mg/min) with DiFMUP as substrate [21]. The
backbone amide signals of His103 to Ala111 and some of the
terminal residues of PRL-3 in the 1H–15N–HSQC spectrum of
PRL-3 taken at pH 7.3 could not be detected. Lowering pH
down to 6.5 did not make new peaks appear, indicating that
missing the amide signals is due to the conformational ﬂexi-
bility. All the backbone amide resonances whose signals could
be detected on the HSQC spectra were assigned, and about
97% of the 1H, 13C side-chain of these assigned backbone
residues, including aromatic rings, were assigned.
Twenty conformers representing the structure of PRL-3
were calculated from 2422 experimental restraints (the statis-
tics are presented in Table 1). The superimposed backbone
traces (N, Ca, C0) of the 20 structures and the ribbon diagram
representation of the secondary structure are shown in
Figs. 2A and B, respectively. The root mean square deviation
of residues 9–158 was 0.76 A for the backbone and 1.27 A for
the heavy atoms.A
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Fig. 4. Overlapping 1H–15N HSQC spectra of PRL-3 obtained in the
presence and absence of ligand ions. The peaks representing the free
form of the protein are shown in black. (A) 0.7 mM PRL-3 with 2 mM
sodium orthovanadate (brown), (B) 0.7 mM PRL-3 with 20 mM
phosphate (purple). The red circled peaks are the backbone amide
protons that appeared in the active site (phosphate loop).
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PRL-3 has a compact (aþ b) structure comprising a central
ﬁve-stranded b sheet decorated with six helices, with a1 and a2
on one side and a3 to a6 on the other (Fig. 2B). The molecule
exists as a monomer judged by the correlation time of 8.7 ns,
which is calculated from the measured T1 and T2 values [22].
The location of the enzyme active site is marked by the con-
served phosphatase signature sequence HCXXGXXR (resi-
dues 103–110), where Cys104 is the enzymatic nucleophile and
Arg110 coordinates with the phosphate group on phosphoty-
rosine (pY). Asp72, which corresponds to Asp226 in PAC-1
and Asp92 in PTEN, is believed to serve as a general acid [23],
and is located in the loop connecting b4 and a3. This loop
has a characteristic WPFDD sequence. The overall folding
topology of PRL-3 is similar to that of the dual speciﬁcity
phosphatases. The arrangement of the strands within the
central b-sheet is in the order 1–2–5–3–4, which is shared by all
members of the DSP family including VHR [24], PTEN [25],
Cdc14 [26], MKP-3 [27] and PAC-1 [28], except that in the case
of the latter two, insertion of an additional b-strand is found
between strands 3 and 4. However, the number, orientations,
and lengths of the secondary structure elements of PRL-3 are
distinct from them.
Fig. 3 compares the structures of PRL-3 (A), PAC-1 (B) and
PTEN (C). a2 of PRL-3, which is a relatively short helix be-
tween b3 and b4, does not exist in PAC-1 or PTEN. While the
overall folding of PRL-3 is similar to the structures of PTENFig. 5. Weighted average of the 15N and 1H chemical shift perturbations (Dd
ions. Bar diagrams of the perturbations that occurred on addition of 2 mM
appeared peaks are shown as yellow circles. The degree of perturbation for va
are perturbed more than 0.3 ppm, yellow residues are new in the spectrum,and PAC-1, the conformation of the loops comprising the
active site diﬀers signiﬁcantly. The side chains of Cys104,
Arg110, and Asp72, in PRL-3 are separated from one another,
whereas the corresponding residues in PTEN are close to-
gether. This structural diﬀerence arises mainly from the posi-
tion of the Asp residue. The general acid loop of PRL-3 is in a
very open conformation, thus the Asp residue is not located
near the phosphate-binding loop. Whereas, the general acid
loop of PTEN is pulled over to the phosphate-binding loop.
The case of PAC-1 is midway between PRL-3 and PTEN.
Since the three residues, Cys104, Arg110, and Asp72 in PRL-3
should be close together for the enzymatic reaction, a sub-
stantial conformational rearrangement of PRL-3 may occur
during binding of the substrate molecule.
3.3. Conformational stabilization in the active site
Without any substrate or inhibitor, the phosphate-binding
loop between b5 and a4 does not converge well due to a lack
of distant constraints. The NMR signals for this region are
very weak or undetectable, indicating that a signiﬁcant con-
formational exchange is present. To determine whether the
conformation of the active site is stabilized on binding of
phosphate or known inhibitors, sodium orthovanadate, p-ni-
trophenylphosphate (pNPP), pY and phosphothreonine (pT),
2D NMR titration experiments were conducted in which these
ions were added. Fig. 4A shows the changes in the 2D NMR
signal of PRL-3 on adding 2.0 mM vanadate ion. New signals¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðdH2 þ 0:2 ðdN2ÞÞp ) of PRL-3 on complex formation with ligand
sodium orthovanadate (A), or 20 mM sodium phosphate (B). Newly
nadate (C) and phosphate (D) is shown in the structure. Green residues
and the remaining residues are blue.
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residues 48, 49, 73, 103, 105–110, and 139. Similarly, 20 mM
phosphate ion was added to the PRL-3 solution (Fig. 4B). The
new signals that appeared on adding phosphate ions were for
residues 48, 49, 73, 103–107, 109, 139, and 145. These signals
indicated that the binding of vanadate or phosphate ions
stabilizes these parts of PRL-3. Figs. 5A and B summarize the
signal changes that occurred on adding vanadate or phosphate
ions, respectively. Figs. 5C and D map the residues in PRL-3
that exhibited major resonance changes on addition of vana-
date (2 mM) or phosphate (20 mM), respectively. These resi-
dues are all located in the loops between b5 and a4, b3 and a2,
a5 and a6, and b4 and a3. These loops form the active site
cleft of PRL-3. Of note, the vanadate and phosphate ions
aﬀect very similar regions of PRL-3. For pNPP, pY and pT,
similar results have been obtained (data not shown) indicating
that the structural stabilization by the ligand binding is a
common phenomenon for these ions.
3.4. Slow- and fast-exchange of vanadate and phosphate ions
The apo-PRL-3 showed signiﬁcant conformational ﬂexi-
bility around the active site. This type of signal loss indicates
that the exchange rate between the diﬀerent conformers is inFig. 6. (A) Strip plot for residues V105 to R110 from the HNCA spectrum of t
the residues spanning 90–120 of free PRL-3 (purple) and the complex with sthe intermediate range compared with the NMR time scale.
These lost signals become detectable when phosphate or van-
adate ions are added to the protein solution. Farooq and his
coworkers reported a similar result for PAC-1 [28]. We as-
signed the NMR signals that appeared, and found that most of
them were from the phosphate-binding loop. Fig. 6A shows a
strip plot of the HNCA spectrum for residues 105–110 of PRL-
3 with 2 mM vanadate, which demonstrates the backbone
NMR signal assignment in this region. The 15N T1 and T2
values for the NH of these residues show that after the vana-
date ion binds, the residues adopt a stabilized structure, which
results in motional parameters similar to those of the rest of
the molecule (Fig. 6B). When we analyzed the NMR signals
while titrating vanadate ions at concentrations from 0 to 2
mM, several NMR signals clearly showed a slow-exchange
pattern on binding of vanadate to PRL-3. Figs. 7A–D show
the NMR signal changes in the 15N–1H HSQC spectra due to
the serial addition of sodium orthovanadate to the PRL-3
solution. In this case, the original signals from the free form of
PRL-3 gradually weakened as new signals from the bound
form appeared simultaneously (Figs. 7A–D, see the boxed
signals for F33, A74, and A140). This indicates that the ex-
change rate between the free and bound states is slower thanhe sodium orthovanadate–PRL-3 complex. (B) 15N T1 and T2 values for
odium orthovanadate (black).
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Fig. 7. Peak traces for the ligand titration in 1H–15N HSQC. 2D spectra show the signal changes that occurred on mixing with (A) 0 mM (black), (B)
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the signals on adding sodium phosphate (Fig. 7E) gradually
shifted in one direction until saturation, indicating that the
exchange rate of phosphate ion between the free and bound
states is faster than the NMR time scale. These observations
suggest that vanadate ions bind to PRL-3 in a slow-tight
binding pattern, while phosphate ions bind in a fast-weak
binding pattern.
3.5. Implication for drug design
The observed structural stabilization and rearrangement
that was brought about by the vanadate and phosphate ions
suggest that we need to consider conformational ﬂexibility to
understand the enzymatic reaction and design an inhibitor.
The structural rearrangement suggests that caution should be
taken when using a rigid X-ray protein structure in structure-
based design studies, as is common in current applications.
An alternative strategy is to design an inhibitor that can bind
to the inactive conformation and inhibit the structural rear-
rangement to the active conformation. For example, STI-571,
an Abelson tyrosine kinase inhibitor, also known as Gleevec,
recognizes the inactive conformation of the kinase and in-hibits its activation [29]. Comparing the apo- and ligand-
bound structures and considering the possible conformational
change that occurs on ligand binding will help us to design
potent, selective drug molecules. The PRL-3 structure re-
ported here gives us the three-dimensional features of this
new family of PRL phosphatases and will assist in the dis-
covery of anti-cancer drugs that act against this enzyme
family.
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